Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany

We analysed time trends in the pulmonary embolism (PE) mortality rates in Germany from 2004 and assessed for an association between the use of anticoagulants and PE caused mortality. We extracted age-specific number of deaths due to PE (ICD-10 I26) from 2004 to 2011 as available from the WHO mortali...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and thrombolysis 2015-11, Vol.40 (4), p.468-473
Main Authors: Pütter, Carolin, von Beckerath, Olga, Sobik, Hanna Maria, Reinecke, Holger, Stausberg, Jürgen, Kröger, Knut
Format: Article
Language:English
Subjects:
Cardiology
Drug Prescriptions
Enoxaparin - administration & dosage
Female
Germany - epidemiology
Hematology
Humans
Male
Medicine
Medicine & Public Health
Pulmonary Embolism - drug therapy
Pulmonary Embolism - mortality
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913
cites cdi_FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913
container_end_page 473
container_issue 4
container_start_page 468
container_title Journal of thrombosis and thrombolysis
container_volume 40
creator Pütter, Carolin
von Beckerath, Olga
Sobik, Hanna Maria
Reinecke, Holger
Stausberg, Jürgen
Kröger, Knut
description We analysed time trends in the pulmonary embolism (PE) mortality rates in Germany from 2004 and assessed for an association between the use of anticoagulants and PE caused mortality. We extracted age-specific number of deaths due to PE (ICD-10 I26) from 2004 to 2011 as available from the WHO mortality databases. In addition we derived defined daily dosage (DDD) of prescribed anticoagulants and the low molecular heparin Enoxaparin for the years 2004–2011 from the statutory health insurance-drug-information system reports. Age-standardized PE mortality per 100,000 decreased from 5.9283 in year 2004 to 4.4876 in 2011 (−24.3 %). Amounts of prescribed anticoagulants increased in this period from 271,810.7 × 1000 DDD to 416,611.8 × 1000 DDD (+53.3 %), that of Enoxaparin increased from 27,071.1 × 1000 DDD in 2004 97,276.5 × 1000 DDD in 2011. The PE mortality is negatively correlated with anticoagulants (−0.9463, p = 0.0004) as well as with enoxaparin (−0.9740, p 
doi_str_mv 10.1007/s11239-015-1265-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717484880</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3818905281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913</originalsourceid><addsrcrecordid>eNp1kU9rFTEUxYMo9ln9AG4k4MbN2JtMMkmWUmotFOyiBXchM3NTU2aSMZlB37c3j1dFCq7u4v7OuX8OIW8ZfGQA6qwwxlvTAJMN451s9DOyY1K1jRL823OyA8NNI1uQJ-RVKQ8AYAzwl-SEd1x1DNSO4E3GMuSwrCFFmjzFmH65xeUQaSjUlZKG4FYc6c-wfqcjDhldCfGeLts0p-jynuLcpymUmc4pr24K657mKqHV4hLz7OL-NXnh3VTwzWM9JXefL27PvzTXXy-vzj9dN4MQfG1EP-I4InjTGelH6KQcfGcGhqztJfRGitbzeqkGDs5DL6TkptcKdSu8Ye0p-XD0XXL6sWFZ7RzKgNPkIqatWKaYElpoDRV9_wR9SFuOdbsD1SndAueVYkdqyKmUjN4uOcz1aMvAHjKwxwxszcAeMrC6at49Om_9jONfxZ-nV4AfgVJb8R7zP6P_6_obFTiSTw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1716783022</pqid></control><display><type>article</type><title>Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany</title><source>Springer Nature</source><creator>Pütter, Carolin ; von Beckerath, Olga ; Sobik, Hanna Maria ; Reinecke, Holger ; Stausberg, Jürgen ; Kröger, Knut</creator><creatorcontrib>Pütter, Carolin ; von Beckerath, Olga ; Sobik, Hanna Maria ; Reinecke, Holger ; Stausberg, Jürgen ; Kröger, Knut</creatorcontrib><description>We analysed time trends in the pulmonary embolism (PE) mortality rates in Germany from 2004 and assessed for an association between the use of anticoagulants and PE caused mortality. We extracted age-specific number of deaths due to PE (ICD-10 I26) from 2004 to 2011 as available from the WHO mortality databases. In addition we derived defined daily dosage (DDD) of prescribed anticoagulants and the low molecular heparin Enoxaparin for the years 2004–2011 from the statutory health insurance-drug-information system reports. Age-standardized PE mortality per 100,000 decreased from 5.9283 in year 2004 to 4.4876 in 2011 (−24.3 %). Amounts of prescribed anticoagulants increased in this period from 271,810.7 × 1000 DDD to 416,611.8 × 1000 DDD (+53.3 %), that of Enoxaparin increased from 27,071.1 × 1000 DDD in 2004 97,276.5 × 1000 DDD in 2011. The PE mortality is negatively correlated with anticoagulants (−0.9463, p = 0.0004) as well as with enoxaparin (−0.9740, p &lt; 0.0001) and of DDD of Enoxaparin per 1000 insured (−0.9682, p &lt; 0.0001). In univariate linear regression model, anticoagulants, Enoxaparin and Enoxaparin per 1000 insured all reach significance (p = 0.0004, p = 4.31 × 10 −5 and p = 0.0001 respectively). Multiple regression models show that Enoxaparin has the most robust effect. Including the time trend in the model does not alter the results. Our study shows that increasing number of prescribed Enoxaparin in an outpatient setting might be one determinant of decreasing PE mortality rate in Germany since 2004.</description><identifier>ISSN: 0929-5305</identifier><identifier>EISSN: 1573-742X</identifier><identifier>DOI: 10.1007/s11239-015-1265-8</identifier><identifier>PMID: 26276107</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cardiology ; Drug Prescriptions ; Enoxaparin - administration &amp; dosage ; Female ; Germany - epidemiology ; Hematology ; Humans ; Male ; Medicine ; Medicine &amp; Public Health ; Pulmonary Embolism - drug therapy ; Pulmonary Embolism - mortality ; Survival Rate</subject><ispartof>Journal of thrombosis and thrombolysis, 2015-11, Vol.40 (4), p.468-473</ispartof><rights>Springer Science+Business Media New York 2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913</citedby><cites>FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26276107$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pütter, Carolin</creatorcontrib><creatorcontrib>von Beckerath, Olga</creatorcontrib><creatorcontrib>Sobik, Hanna Maria</creatorcontrib><creatorcontrib>Reinecke, Holger</creatorcontrib><creatorcontrib>Stausberg, Jürgen</creatorcontrib><creatorcontrib>Kröger, Knut</creatorcontrib><title>Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany</title><title>Journal of thrombosis and thrombolysis</title><addtitle>J Thromb Thrombolysis</addtitle><addtitle>J Thromb Thrombolysis</addtitle><description>We analysed time trends in the pulmonary embolism (PE) mortality rates in Germany from 2004 and assessed for an association between the use of anticoagulants and PE caused mortality. We extracted age-specific number of deaths due to PE (ICD-10 I26) from 2004 to 2011 as available from the WHO mortality databases. In addition we derived defined daily dosage (DDD) of prescribed anticoagulants and the low molecular heparin Enoxaparin for the years 2004–2011 from the statutory health insurance-drug-information system reports. Age-standardized PE mortality per 100,000 decreased from 5.9283 in year 2004 to 4.4876 in 2011 (−24.3 %). Amounts of prescribed anticoagulants increased in this period from 271,810.7 × 1000 DDD to 416,611.8 × 1000 DDD (+53.3 %), that of Enoxaparin increased from 27,071.1 × 1000 DDD in 2004 97,276.5 × 1000 DDD in 2011. The PE mortality is negatively correlated with anticoagulants (−0.9463, p = 0.0004) as well as with enoxaparin (−0.9740, p &lt; 0.0001) and of DDD of Enoxaparin per 1000 insured (−0.9682, p &lt; 0.0001). In univariate linear regression model, anticoagulants, Enoxaparin and Enoxaparin per 1000 insured all reach significance (p = 0.0004, p = 4.31 × 10 −5 and p = 0.0001 respectively). Multiple regression models show that Enoxaparin has the most robust effect. Including the time trend in the model does not alter the results. Our study shows that increasing number of prescribed Enoxaparin in an outpatient setting might be one determinant of decreasing PE mortality rate in Germany since 2004.</description><subject>Cardiology</subject><subject>Drug Prescriptions</subject><subject>Enoxaparin - administration &amp; dosage</subject><subject>Female</subject><subject>Germany - epidemiology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Pulmonary Embolism - drug therapy</subject><subject>Pulmonary Embolism - mortality</subject><subject>Survival Rate</subject><issn>0929-5305</issn><issn>1573-742X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNp1kU9rFTEUxYMo9ln9AG4k4MbN2JtMMkmWUmotFOyiBXchM3NTU2aSMZlB37c3j1dFCq7u4v7OuX8OIW8ZfGQA6qwwxlvTAJMN451s9DOyY1K1jRL823OyA8NNI1uQJ-RVKQ8AYAzwl-SEd1x1DNSO4E3GMuSwrCFFmjzFmH65xeUQaSjUlZKG4FYc6c-wfqcjDhldCfGeLts0p-jynuLcpymUmc4pr24K657mKqHV4hLz7OL-NXnh3VTwzWM9JXefL27PvzTXXy-vzj9dN4MQfG1EP-I4InjTGelH6KQcfGcGhqztJfRGitbzeqkGDs5DL6TkptcKdSu8Ye0p-XD0XXL6sWFZ7RzKgNPkIqatWKaYElpoDRV9_wR9SFuOdbsD1SndAueVYkdqyKmUjN4uOcz1aMvAHjKwxwxszcAeMrC6at49Om_9jONfxZ-nV4AfgVJb8R7zP6P_6_obFTiSTw</recordid><startdate>20151101</startdate><enddate>20151101</enddate><creator>Pütter, Carolin</creator><creator>von Beckerath, Olga</creator><creator>Sobik, Hanna Maria</creator><creator>Reinecke, Holger</creator><creator>Stausberg, Jürgen</creator><creator>Kröger, Knut</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20151101</creationdate><title>Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany</title><author>Pütter, Carolin ; von Beckerath, Olga ; Sobik, Hanna Maria ; Reinecke, Holger ; Stausberg, Jürgen ; Kröger, Knut</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Cardiology</topic><topic>Drug Prescriptions</topic><topic>Enoxaparin - administration &amp; dosage</topic><topic>Female</topic><topic>Germany - epidemiology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Pulmonary Embolism - drug therapy</topic><topic>Pulmonary Embolism - mortality</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pütter, Carolin</creatorcontrib><creatorcontrib>von Beckerath, Olga</creatorcontrib><creatorcontrib>Sobik, Hanna Maria</creatorcontrib><creatorcontrib>Reinecke, Holger</creatorcontrib><creatorcontrib>Stausberg, Jürgen</creatorcontrib><creatorcontrib>Kröger, Knut</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and thrombolysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pütter, Carolin</au><au>von Beckerath, Olga</au><au>Sobik, Hanna Maria</au><au>Reinecke, Holger</au><au>Stausberg, Jürgen</au><au>Kröger, Knut</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany</atitle><jtitle>Journal of thrombosis and thrombolysis</jtitle><stitle>J Thromb Thrombolysis</stitle><addtitle>J Thromb Thrombolysis</addtitle><date>2015-11-01</date><risdate>2015</risdate><volume>40</volume><issue>4</issue><spage>468</spage><epage>473</epage><pages>468-473</pages><issn>0929-5305</issn><eissn>1573-742X</eissn><abstract>We analysed time trends in the pulmonary embolism (PE) mortality rates in Germany from 2004 and assessed for an association between the use of anticoagulants and PE caused mortality. We extracted age-specific number of deaths due to PE (ICD-10 I26) from 2004 to 2011 as available from the WHO mortality databases. In addition we derived defined daily dosage (DDD) of prescribed anticoagulants and the low molecular heparin Enoxaparin for the years 2004–2011 from the statutory health insurance-drug-information system reports. Age-standardized PE mortality per 100,000 decreased from 5.9283 in year 2004 to 4.4876 in 2011 (−24.3 %). Amounts of prescribed anticoagulants increased in this period from 271,810.7 × 1000 DDD to 416,611.8 × 1000 DDD (+53.3 %), that of Enoxaparin increased from 27,071.1 × 1000 DDD in 2004 97,276.5 × 1000 DDD in 2011. The PE mortality is negatively correlated with anticoagulants (−0.9463, p = 0.0004) as well as with enoxaparin (−0.9740, p &lt; 0.0001) and of DDD of Enoxaparin per 1000 insured (−0.9682, p &lt; 0.0001). In univariate linear regression model, anticoagulants, Enoxaparin and Enoxaparin per 1000 insured all reach significance (p = 0.0004, p = 4.31 × 10 −5 and p = 0.0001 respectively). Multiple regression models show that Enoxaparin has the most robust effect. Including the time trend in the model does not alter the results. Our study shows that increasing number of prescribed Enoxaparin in an outpatient setting might be one determinant of decreasing PE mortality rate in Germany since 2004.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>26276107</pmid><doi>10.1007/s11239-015-1265-8</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0929-5305
ispartof Journal of thrombosis and thrombolysis, 2015-11, Vol.40 (4), p.468-473
issn 0929-5305
1573-742X
language eng
recordid cdi_proquest_miscellaneous_1717484880
source Springer Nature
subjects Cardiology
Drug Prescriptions
Enoxaparin - administration & dosage
Female
Germany - epidemiology
Hematology
Humans
Male
Medicine
Medicine & Public Health
Pulmonary Embolism - drug therapy
Pulmonary Embolism - mortality
Survival Rate
title Prescription of enoxaparin is associated with decreasing pulmonary embolism mortality rate in Germany
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A55%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prescription%20of%20enoxaparin%20is%20associated%20with%20decreasing%20pulmonary%20embolism%20mortality%20rate%20in%20Germany&rft.jtitle=Journal%20of%20thrombosis%20and%20thrombolysis&rft.au=P%C3%BCtter,%20Carolin&rft.date=2015-11-01&rft.volume=40&rft.issue=4&rft.spage=468&rft.epage=473&rft.pages=468-473&rft.issn=0929-5305&rft.eissn=1573-742X&rft_id=info:doi/10.1007/s11239-015-1265-8&rft_dat=%3Cproquest_cross%3E3818905281%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c442t-4bdedde0f9695fd0655cf69c1e13b50b9543f22658020af0b45529b87e834f913%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1716783022&rft_id=info:pmid/26276107&rfr_iscdi=true